Primary Care News: Highlights from 7 Must-Read Studies

Prioritizing Blood-Based CRC Tests May Lead to Higher Costs and Worse Outcomes, Study Finds

Slideshow

At-a-glance: Research on opioid addiction, exergaming for Alzheimer patients, medical cannabis for chronic pain, and more.

What is new in primary care research? We will give you some hints: a new finding in opioid addiction research, bacteria-fighting microbeads, virtual reality gaming that helps Alzheimer patients, efficacy of medical marijuana in pain treatment, and more. Click through the slideshow above to get the highlights from 7 new studies that could impact your practice soon.Â

Related Content

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Annual colorectal cancer screening with FIT was the most cost-effective strategy among patients with low adherence, researchers reported.

Keith A. Reynolds

October 1st 2024

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Grace Halsey

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

October 25th 2023

DEA Amends Telehealth Prescribing Rules, Including Special Registration for Schedule II-V Medications

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Austin Littrell

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

The DEA action includes 3 new telehealth rules that make permanent several flexibilities enacted during the pandemic and also establish new protections for patients.

Patient Care Staff

Prioritizing Blood-Based CRC Tests May Lead to Higher Costs and Worse Outcomes, Study Finds

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

Related Content

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Annual colorectal cancer screening with FIT was the most cost-effective strategy among patients with low adherence, researchers reported.

Keith A. Reynolds

October 1st 2024

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Grace Halsey

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

October 25th 2023

DEA Amends Telehealth Prescribing Rules, Including Special Registration for Schedule II-V Medications

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Austin Littrell

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

The DEA action includes 3 new telehealth rules that make permanent several flexibilities enacted during the pandemic and also establish new protections for patients.

Patient Care Staff